Clinical Trial Update: Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial entry describes evaluating human mesenchymal stem cells and monoclonal antibodies for mild cognitive impairment and early Alzheimer's d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Human Mesenchymal Stem Cells (mesenchymal stem cells)
• Monoclonal antibodies (monoclonal antibodies)

Snippet

Sponsor: Bernard (Barry) Baumel | Conditions: Mild Cognitive Impairment, Early Alzheimer's Disease | Phase 2 | Status: NOT_YET_RECRUITING